What is DotLab?
DotLab is a pioneering women's healthcare technology firm that has developed DotEndo, a non-invasive blood test designed to identify active endometriosis. By measuring specific biomarkers, the company provides a diagnostic solution that functions independently of hormonal cycles or symptom severity. This innovation is particularly vital for addressing unexplained infertility and reducing the diagnostic odyssey that patients often endure. By providing clinicians with actionable insights, DotLab is effectively transforming the standard of care, moving away from invasive procedures toward data-driven, early-stage intervention. The company's market position is bolstered by its ability to address a massive, underserved demographic, making it a high-impact entity in the life sciences space.
How much funding has DotLab raised?
DotLab has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2019): $10M with participation from CooperSurgical, Luxor Capital Group, Wilson Sonsini Goodrich & Rosati, and TriplePoint Venture Growth BDC
Key Investors in DotLab
Luxor Capital Group
Luxor Capital Group is a New York-based investment management firm that provides sophisticated financial solutions and capital strategies to institutional investors and high-net-worth individuals.
Wilson Sonsini Goodrich & Rosati
A premier law firm specializing in legal services for technology and life sciences enterprises, with deep expertise in venture financing and corporate growth strategies.
TriplePoint Venture Growth BDC
A global provider of financing for high-growth companies, focusing on maximizing returns through debt and equity-linked instruments for venture-backed businesses.
What's next for DotLab?
With this major enterprise-level funding, DotLab is well-positioned to accelerate the commercialization and clinical adoption of its diagnostic platform. The strategic capital will likely be deployed to scale operations, expand clinical validation studies, and enhance the accessibility of DotEndo for both patients and healthcare providers. As the company moves beyond its initial development phase, the focus will shift toward integrating its diagnostic tools into broader clinical workflows, potentially setting a new benchmark for endometriosis management. Future growth will likely hinge on the company's ability to navigate regulatory landscapes and establish partnerships with major health systems, further cementing its role as a leader in precision medicine for women.
See full DotLab company page
